Diagnostic rheumatoid arthritis has a new marker

recently, nature-newsletter published a study of disease-related and marker molecules called rheumatoid arthritis (RA). The article, from the Li Zhanguo Research Group of the Rheumatology Immunology Research Institute of Peking University People's Hospital, found that the sSR-A level of RA patients increased significantly and was directly related to the clinical symptoms and immune status indicators of the disease. The results show that sSR-A is a new biomarker for RA diagnosis, especially for serum-negative and early RA diagnosis, while targeting sSR-A may be a new treatment strategy.
the China Science Journal that RA is a common autoimmune disease with high disability. With more than 30 million patients worldwide, the disease is characterized by devastating arthritis and autoimmune abnormalities. At present, RA serum diagnosis is mainly based on rheumatoid factors and anti-CEP detection. However, there are still a large number of patients in the early stages of the disease, or even for many years without biomarkers, which make clinical diagnosis and treatment difficult, resulting in delayed treatment and disability. Early diagnosis is essential to improve RA outcomes. However, current diagnostic tools are limited in sensitivity to early patients, resulting in a large number of patients who are unable to be properly treated and have disabilities due to delayed diagnosis.
In view, the team, in a large-scale multi-center study involving training and validation queues of 3,262 participants, conducted by researchers from Zhejiang University, Southern Medical University and Baotou Medical College, found that sSR-A was a disease-creating molecule of RA that promotes inflammatory T-cells and inflammatory factors. In addition, the team used gene knock-out sSR-A--/-model studies to prove that sSR-A can promote the onset of arthritis and the exacerbation of the disease, targeted inhibition of sSR-A can alleviate the symptoms of arthritis.
further confirmed that sSR-A protein can promote collagen-induced arthritis, accelerate the progression of the disease, increase the degree of disease, membrane inflammation and bone erosion, and enhance the inflammatory response of Th17 cell-mediated; A neutral antibody and sSR-A inhibitor fucoidan targeted inhibitor sSR-A, can slow the progression of the disease, reduce the disease and bone damage, reduce the level of the inflammatory factor IL-17A in the serum, showing obvious therapeutic effect.
industry insiders say the discovery of sSR-A clinical value is one of the most important advances in RA immunodiagnosis research in recent years, providing a test basis for early diagnosis, reduction of misdiagnosis and further immunotherapy of the disease. (Source: Zhang Siwei, China Science Journal)
relevant paper information: